Skip to Main Content
Book cover for Oxford Handbook of Obstetrics and Gynaecology (3 edn) Oxford Handbook of Obstetrics and Gynaecology (3 edn)

A newer edition of this book is available.

Close

Contents

Book cover for Oxford Handbook of Obstetrics and Gynaecology (3 edn) Oxford Handbook of Obstetrics and Gynaecology (3 edn)
Disclaimer
Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always … More Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up to date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding.

The menstrual cycle involves the coordinated hormonal control of the endometrium allowing pregnancy or regular shedding (periods). Peptide hormones from the hypothalamus and pituitary direct the ovary to produce steroid hormones (HPO axis), which in turn control the endometrium (see Fig. 15.1). The process is complex and aspects of its initiation, control, and cessation are not fully understood. The average ages of menarche and menopause are 12.8 (falling) + 51, respectively. Day 1 of a cycle is the first day of fresh bleeding and this should always be clarified on history of LMP.

 The menstrual cycle. Reproduced from Sanders S, Dawson J, Datta S, et al. (eds) (2005). Oxford Handbook for the Foundation Programme. Oxford: OUP. By permission of Oxford University Press.
Fig. 15.1

The menstrual cycle. Reproduced from Sanders S, Dawson J, Datta S, et al. (eds) (2005). Oxford Handbook for the Foundation Programme. Oxford: OUP. By permission of Oxford University Press.

Pulsatile release of hypothalamic GnRH → anterior pituitary to produce FSH.

FSH promotes ovarian follicular development → recruitment of a dominant follicle containing oocyte.

Follicular granulosa cells produce oestrogen → endometrial proliferation.

↑ Oestrogen levels → −ve feedback on the hypothalamo-pituitary (HP) axis (via follicular inhibin) to stop further FSH production.

Increasing dominant follicle oestrogen (positive feedback via follicular activin) → altered hypothalamic GnRH pulsatility → pituitary production of LH—LH surge 36h before ovulation.

The follicle collapses down to become the corpus luteum (CL) (‘yellow body’), which produces oestrogen and progesterone (from theca cells).

Progesterone and oestrogen act on an oestrogen-primed endometrium to induce secretory changes → thickening and ↑ vascularity.

The corpus luteum has a fixed lifespan of 14 days (programmed cell death) before undergoing involution → corpus albicans (‘white body’).

If implantation occurs, hCG (luteotrophic) ‘rescue’ of the CL allows continued production of progesterone to support the endometrium.

In the absence of pregnancy, CL degeneration → a rapid fall in progesterone and oestrogen, initiating menstruation.

Rapid ↓ in steroids → shedding of the unused endometrium.

Inflammatory mediators (PGs, ILs, and tumour necrosis factor (TNF)) → vasospasm (approx. 24h) in spiral end arteries → hypoxia and endometrial devitalization.

Vasodilatation and spiral artery collapse → loss of the layer and bleeding from vessels.

Endometrium lost down to basalis layer (1/3 of loss reabsorbed).

Complex vascular changes controlled by above secondary messengers, also → natural haemostatic mechanisms including platelet plugs, coagulation cascade, and fibrinolysis.

All steroid hormones now at basal level, negative feedback is lifted, and GnRH–FSH production can begin a new cycle.

Normal cycle or pathological?

Ovulatory cycles vary, but are usually 21–32 days with a basically regular pattern.

Ovulatory cycles that vary do so due to the follicular phase (luteal phase fixed).

Shorter or longer cycles usually result from oligo-ovulation/anovulation.

After menarche, cycles often irregular for months or for several years until maturation of the HPO axis reliably triggers ovulation.

Peri-menopausal periods are commonly irregular (usually ↑ cycle length) due to ovarian resistance to gonadotrophins and anovulatory cycles.

graphic Do NOT blame erratic, chaotic, or constant bleeding in women >45yrs on ‘the menopausal change’—it needs further investigation to exclude genital tract cancer.

Nearly all women will experience some menstrual irregularity in timing or flow at some stage—many cases are transient.

Bleeding and pain: what is normal?

Bleeding can be for 1–7 days with an average of 3–5 days.

Reported amount of blood loss is highly variable.

Periods described as ‘heavy’ should always be viewed as such.

Pain is ‘normal’ (vasospasm and ischaemia), but is highly variable.

graphic Pain interfering with normal functioning needs to be addressed.

graphic Bleeding between periods (IMB), after intercourse (PCB), or totally erratic/constant bleeding is always abnormal.

1° amenorrhoea is lack of menstruation by age 16 in the presence of 2° sexual characteristics or 14 in their absence.

2° amenorrhoea is an absence of menstruation for 6mths.

Emphasis on:

Sexual activity, risk of pregnancy, and type of contraceptive used.

Galactorrhoea or androgenic symptoms (weight gain, acne, hirsutism).

Menopausal symptoms (night sweats, hot flushes).

Previous genital tract surgery (intrauterine instrumentation or LLETZ).

Issues with eating or excessive exercise.

Drug use (especially dopamine antagonists for psychiatric conditions).

BMI <17/>30, hirsutism, 2° sexual characteristics (Tanner staging).

Stigmata of endocrinopathies (including thyroid) or Turner’s syndrome.

Evidence of virilization (deep voice, male pattern balding, cliteromegaly).

Abdominal: may show masses due to tumours or genital tract obstruction.

Pelvic: imperforate hymen, blind ending vaginal septum, absence of cervix and uterus.

Must be guided by the diagnosis and fertility wishes. Options include:

Treat any underlying causes including attaining normal BMI.

Cabergoline or surgery for hyperprolactinaemia.

Cyclical withdrawal bleeds (COCP for PCOS).

HRT for POF.

Relief of genital tract obstruction: cervical dilation, hysteroscopic resection, incision of hymen.

Specific treatment for endocrinopathies and tumours.

▶ Major congenital abnormalities, AIS, etc. should be managed by multidisciplinary teams in specialist centres.

Common causes of amenorrhoea
Physiological causes

graphic Pregnancy must always be excluded.

Lactation.

Menopause.

Iatrogenic causes

Progestagenic contraceptives: Depo-Provera®, Mirena IUS®, Nexplanon®, POP.

Therapeutic progestagens, continuous COCP use, GnRH analogues, rarely danazol.

Investigations for amenorrhoea

graphic Pregnancy test.

FSH/LH:↑ in premature ovarian failure (POF), ↓ hypothalamic causes (not useful in PCOS).

Testosterone and sex hormone-binding globulin (SHBG) are most useful for PCOS.

Prolactin should always be tested.

TFTs.

Pelvic ultrasound:

can define anatomical structures, congenital abnormalities, Asherman’s syndrome, haematometra, and PCOS morphology

can indicate physiological activity or endometrial atrophy in POF.

Karyotype if uterus absent or suspicion of Turner’s syndrome.

Specific tests for endocrinopathies where there is clinical suspicion.

Pathological causes of amenorrhoea

Hypothalamic:

functional—stress, anorexia, excessive exercise, pseudocyesis

non-functional— space-occupying lesion (SOL), surgery, radiotherapy, Kallman’s syndrome (1° GnRH deficiency).

Anterior pituitary:

micro- or macroadenoma (prolactinoma) or other SOL

surgery

Sheehan’s syndrome (post-partum pituitary failure).

Ovarian:

PCOS

POF

resistant ovary syndrome

ovarian dysgenesis, especially due to Turner’s syndrome (45XO).

Genital tract outflow obstruction:

imperforate hymen

transverse vaginal septum

cervical stenosis

Asherman’s syndrome (iatrogenic intrauterine adhesions).

Agenesis of uterus and müllerian duct structures: sporadic or associated with AIS.

Endocrinopathies:

hyperprolactinaemia

Cushing’s syndrome

severe hypo/hyperthyroidism

CAH.

Oestrogen—or androgen—secreting tumours: usually ovarian or adrenal, e.g. granulosa-thecal cell tumours and gynandroblastoma.

When cycles are longer than 32 days they usually represent anovulation or intermittent ovulation. Transient oligomenorrhoea is common (‘stress’ or emotionally related causes are often cited) and usually self-limiting.

Causes of oligomenorrhoea

Similar to many of the causes of 2° amenorrhoea:

PCOS is the commonest cause (see graphic Polycystic ovarian syndrome, p. 570).

Borderline low BMI.

Obesity without PCOS.

Ovarian resistance leading to anovulation, e.g. incipient POF, is rare, but important,

Milder degrees of hyperprolactinaemia need to be excluded as well as mild thyroid disease.

Management of oligomenorrhoea
What does the patient want? Regular periods or fertility?

Provide reassurance.

Treat any underlying causes as for amenorrhoea.

It is not uncommon for no cause to be found, but serious pathology must be excluded.

Attain normal BMI (weight loss or gain as appropriate).

Provide regular cycles:

COCP or cyclical progestagens

for PCOS a minimum of 3 periods/yr is recommended to ↓ the risk of endometrial hyperplasia due to unopposed oestrogen.

Full fertility screening should be performed if ovulation induction is required.

dysmenorrhoea: the pain has no obvious organic cause.

dysmenorrhoea: the pain is due to an underlying condition.

Pain is highly subjective and varies greatly between women. However, if a woman describes her periods as unacceptably painful, then they are!

Timing and severity of pain (including degree of functional loss): commonly premenstrual pain ↑ in the first 1–2 days of bleeding, then eases.

Pelvic pain and deep dyspareunia (may signify pelvic pathology).

Previous history of PID or STIs.

Previous abdominal or genital tract surgery (may cause adhesions).

Abdominal exam to exclude pelvic masses.

Pelvic exam; cervical excitation, adnexal tenderness, mobility, and masses.

STI screen (including Chlamydia swab).

USS, endometriomata, PID sequelae, fibroids, congenital abnormalities.

Laparoscopy is usually reserved for women with USS abnormalities, medical treatment failures, or those with concomitant subfertility.

▶ When no disease is identified then ovulation suppression by tricycling COCP or GnRH analogues for up to 6–12mths will limit the number of ‘periods’ and therefore pain. This is an empirical trial of hormonal therapy.

▶ Pain clinic, psychological support, and self-help groups may be of benefit to some women who wish to maintain their fertility, especially when they have other pelvic pain symptoms.

1° dysmenorrhoea

Pain in the menstrual cycle is a feature of ovulatory cycles and is due to uterine vasospasm and ischaemia, nervous sensitization due to PGs and other inflammatory mediators, and uterine contractions. A maternal or sibling history of dysmenorrhoea is very common and the problem usually starts soon after menarche. Theories accounting for 1° dysmenorrhoea include:

Abnormal PG ratios or sensitivity.

Neuropathic dysregulation.

Venous pelvic congestion.

Psychological causes.

2° dysmenorrhoea

Underlying causes include:

Endometriosis.

Adenomyosis.

PID.

Pelvic adhesions.

Fibroids (though not always causal).

Cervical stenosis (iatrogenic post-LLETZ or instrumentation).

Asherman’s syndrome.

Congenital abnormalities causing genital tract obstruction, e.g. non-communicating cornua.

Management of dysmenorrhoea

Appropriate reassurance and analgesia may be all that is required.

Symptom control:

mefenamic acid 500mg tds with each period is effective

COCP to abolish ovulation

data on Mirena IUS® demonstrate benefit

paracetamol, hot-water bottles, etc., may be helpful for some

TENS, vitamin B1, and magnesium may be of benefit to some women.

Treat any underlying causes:

Endometriosis—COCP, progestagens, GnRH analogues

antibiotics for PID

relief of obstruction (usually surgical).

Therapeutic laparoscopy—for above indications: gold standard for diagnosis + management of endometriosis/adhesions/complicated PID.

Hysterectomy is now rare for this indication alone.

Laparoscopic uterine nerve ablation (LUNA) is not currently recommended.

Dysfunctional uterine bleeding (DUB) is a diagnosis of exclusion and is defined as any abnormal uterine bleeding in the absence of pregnancy, genital tract pathology, or systemic disease.

Menorrhagia is the commonest symptom and DUB will ultimately be the cause in 50–60% of women with this symptom.

Menorrhagia is responsible for 15–20% of gynaecological referrals to hospital and an even higher proportion of GP gynae consultations.

graphic Objective measures of blood loss >80mL are clinically meaningless and should not be used outside research. If periods are reported as unacceptably heavy, then they are!

The exact causes of DUB are unknown. Proposed mechanisms at the endometrial level include:

Abnormal PG ratios (+ other inflammatory mediators) favouring vasodilatation and platelet non-aggregation.

Excessive fibrinolysis.

Defects in expression/function of matrix metalloproteinases (MMPs), vascular growth factors, and endothelins.

Aberrant steroid receptor function.

Defects in the endomyometrial junctional zone.

The medical treatments tend to reflect the underlying pathologies (see graphic Dysfunctional uterine bleeding (DUB): diagnosis and investigations, p. 514).

DUB at a glance

Menorrhagia is the commonest gynaecological symptom you will see, and most of these women will have DUB.

DUB is an umbrella term and only diagnosed after exclusion of pathology.

Women under 45 can safely be treated without investigation in the absence of erratic bleeding.

TVS is the first-line investigation if the woman is >45yrs with failed medical therapy to identify endometrial polyps + fibroids (i.e. focal pathology).

In the presence of erratic bleeding in women >45yrs an endometrial biopsy is required.

The majority of women will respond to medical therapy, especially tranexamic ± mefenamic acid.

The Mirena IUS® is an excellent treatment that significantly reduces the number of women requiring surgery.

Surgery should only be used in women who have completed their family and have had failed adequate medical therapy.

Endometrial ablation: microwave endometrial ablation (MEA), balloon ablation, or Novasure are easy to perform and should be offered before hysterectomy.

Hysterectomy has higher morbidity and cost, but is a guaranteed cure, and long-term satisfaction rates are high.

Heavy and/or prolonged vaginal bleeding (with clots and flooding): irregular, heavy periods usually occur at the extremes of reproductive life (post-menarche and peri-menopausal).

May be associated with dysmenorrhoea.

Systemic symptoms of anaemia and disruption of life due to bleeding.

A smear history and contraceptive use are vital information.

graphic Totally erratic bleeding, IMB, or PCB should prompt a search for cervical or endometrial pathology.

Anaemia.

Abdomino-pelvic examination is usually normal. If the uterus is significantly enlarged, fibroids are likely.

Differential diagnosis for DUB

Submucous fibroids.

Adenomyosis.

Endometrial polyps, hyperplasia, or cancer.

Very rarely, hypothyroidism or coagulation defects.

graphic Pregnancy should always be considered and excluded.

FBC (Hb + MCV).

Ferritin, TFTs, and clotting screens are not routine investigations—only consider if clinically indicated.

Cervical smears are not done opportunistically if smear history normal.

STI screen including Chlamydia.

The risk of endometrial pathology in women <45yrs is very small so no further investigation required—treat and await clinical response.

If >45yrs, with risk factors for endometrial disease, or no clinical response:

TVS USS—is good for identifying fibroids and polyps, and measuring endometrial thickness. The risk of endometrial pathology with a normal TVS USS is small, but it may be less accurate during menstruation

pipelle endometrial biopsy to exclude hyperplasia or cancer

hysteroscopy and biopsy (preferably outpatient) may be appropriate as above or if there is no response to initial medical treatment

hysteroscopy is mandatory with erratic bleeding in a woman >45yrs if USS reveals focal pathology, e.g. polyp, or is unable to assess the whole endometrium, biopsy is inadequate, or bleeding is persistent or repeated.

Releases measured doses of levonorgestrel into the endometrial cavity for 5yrs inducing an atrophic endometrium. Blood loss ↓ by up to 90% and ~30% will be amenorrhoeic at 12mths.

Provides contraception.

Side effects: insertional issues, irregular PV bleeding for first 4–6mths (usually abates); progestagenic side effects are rare due to minimal systemic absorption.

▶ This IUS has resulted in a major ↓ in number of hysterectomies.

Antifibrinolytics: tranexamic acid 1g tds days 1–4 (40% ↓ in loss):

safe, non-hormonal, non-contraceptive

side effects—leg cramps, minor GI upset. Caution in cardiac disease.

NSAIDS: mefenamic acid 500mg tds days 1–5 (20–30% ↓ in loss and significant ↓ in dysmenorrhoea):

safe, non-hormonal/contraceptive.

side effects—GI upset including ulceration, renal impairment. Caution if asthmatic, CV disease, renal impairment, peptic ulcer.

COCP: 20–30% ↓ loss and improvement in dysmenorrhoea:

provides contraception

for cautions and side effects see graphic Combined oral contraceptive pill: overview, p. 622

Oral progestagens: are generally of no benefit in regular menorrhagia other than—short term continuous treatment to stop bleeding.

Mirena IUS®: as above.

Tranexamic and mefenamic acid are useful to ↓ loss during periods.

COCP will also regulate an irregular cycle (safe up to the menopause if no other cardiovascular risk factors).

Cyclical (days 5–26) Norethisterone 5mg tds or medroxyprogesterone acetate 5–10mg tds:

regulates cycle, but little evidence to suggest ↓ in loss

side effects—bloating, headache.

Where first-line therapy has failed, further medical treatment may be used in very anaemic women, bleeding continuously, having their life disrupted, or who have cautions or contraindications to surgery.

GnRH analogues can achieve amenorrhoea quickly by inducing a medical menopausal state: side effects—vasomotor symptoms and use limited to 6–12mths maximum due to bone loss.

High-dose progestagens: medroxyprogesterone acetate 10mg tds continuously will induce amenorrhoea, but may be time-limited due to side effects as before.

▶ Danazol and ethamsylate are no longer indicated.

Choice of management for DUB

This will depend on:

Treatment being directed to symptom relief and improved QoL.

A woman’s wishes for treatment being of prime importance.

Her reproductive wishes and contraceptive needs.

Whether her periods are regular or irregular.

▶ Many women may just need reassurance that there is no serious cause.

▶ Women may continue medical treatments for as long as they are beneficial.

▶ Anaemia should be corrected by treating the underlying cause of bleeding and using ferrous sulphate (or equivalent) to replace lost iron stores.

NICE. (2010). Heavy menstrual bleeding: understanding NICE guidance. NICE guideline CG44. graphic  www.nice.org.uk/CG044publicinfo

Surgery should be reserved for the minority of women who fail to respond to medical management.

graphic Women have to be certain their families are complete before surgery.

Destruction of the endometrium down to the basalis layer is effective for most women and should be offered to all for consideration.

Methods include:

Microwave (MEA).

Thermal balloon (Thermachoice).

Novasure (electrical impedance).

▶ Hysteroscopic resection, or rollerball ablation, are now used much less often due to ↑ operative complications.

graphic Endometrial ablation is less effective if the endometrial cavity is >10cm.

Typical endometrial ablation results in normal size cavities:

80–90% of women are significantly improved.

30% will become amenorrhoeic.

20% will need a second procedure by 5yrs.

The newer procedures above are generally very safe and straightforward; however, there is a small risk of bleeding, infection, uterine perforation, and failed procedure.

They are generally carried out under GA, but may occasionally be done under cervical block.

Hysterectomy is the only guaranteed cure for DUB, but RCTs have shown higher morbidity, longer recovery, and financial costs compared to endometrial ablation.

Complications include haemorrhage; infection; and bladder, ureteric, or bowel injury (<1%). Death is extremely rare.

Long-term satisfaction rates for hysterectomy are generally very high and regardless of method most women report improved sexual function—as one patient put it, ‘I actually have sex now I’m not bleeding all the time’.

Current evidence regarding method of hysterectomy

Vaginal hysterectomy is the route of choice over abdominal, where possible, as recovery, post-operative pain, and cost are reduced.

Laparoscopic-assisted vaginal hysterectomy (LAVH) takes longer than abdominal or vaginal, and has higher rates of urinary tract injury. No evidence supports routine use of this method.

Subtotal hysterectomy is quicker and has a lower risk of bladder injury, but the possible improved sexual satisfaction rates are as yet unproven. There is a small risk of continuing light menstruation if residual endometrial cells are left, and women will continue to require smear tests.

Any definition of premenstrual syndrome should include:

Distressing psychological, physical, and/or behavioural symptoms.

Occurrence during the luteal phase of the menstrual cycle (or cyclically after hysterectomy with ovarian conservation).

Significant regression of symptoms with onset of or during the period.

In the general population 15% of women are asymptomatic, 50% have mild premenstrual syndrome (PMS) symptoms, 30% moderate, and 5–10% severe.

Probable multiple aetiologies, but cyclical ovarian activity is likely to be the central component (ovarian ‘trigger’, such as ovulation, may initiate a cascade of events). A central increased responsiveness to a combination of steroids, chemical messengers (E2/serotonin, progesterone/GABA), and psychological sensitivity may play a part.

Most women self-diagnose.

A detailed history can suggest a diagnosis of PMS, but only prospective assessment with a symptom diary can establish its true nature.

A variety of symptom charts are available from the National Association of Premenstrual Syndrome.

Moderate/severe PMS involves disruption of work and interpersonal relationships, or interference with normal activities.

DSM-IV diagnostic criteria (USA) for premenstrual dysphoric disorder are considered equivalent to severe PMS.

▶ It is important to exclude organic disease and significant psychiatric illness. Perimenopausal women may have increasing premenstrual symptoms as well as menopausal symptoms.

DSM-IV criteria for premenstrual dysphoric disorder

At least 5 symptoms present for most of the late luteal phase with remission within a few days of onset of menses and absence of symptoms in the week post menses. At least one symptom must be from the following first four:

Markedly depressed mood, feelings of hopelessness, or self-deprecation.

Marked anxiety, tension (being ‘on edge’).

Marked affective lability (e.g. feeling suddenly sad or tearful).

Persistent and marked anger/irritability/increased conflicts.

Decreased interest in usual activities (school, friends, hobbies).

Subjective sense of difficulty in concentrating.

Lethargy, easy fatiguability/lack of energy.

Marked change in appetite, overeating, or specific food cravings.

Hypersomnia or insomnia.

Subjective sense of being overwhelmed or out of control.

Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a sense of ‘bloating’, weight gain.

National Association of Premenstrual Syndrome. graphic  www.pms.org.uk

A meta-analysis suggests no benefit of progesterone pessaries, suppositories, depot injections, or oral formulations.

COCP: appears useful for some women. However, some women have PMS-type progestagenic side effects or symptoms during the pill-free interval. Yasmin® contains drospirenone with a better side effect profile, and newer pills with a 2–4-day break or with no pill-free interval may be more therapeutic.

Danazol: 4 RCTs report benefit for PMS, but there are significant masculinizing side effects. Treatment in luteal phase only is effective for breast tenderness.

Oestrogen: transdermal oestrogen or implants at doses sufficient to suppress ovulation are not currently licensed, but they are a well established and accepted treatment of PMS. Estradiol patch 100 micrograms twice weekly with a progestogen (cyclical basis). Implants generally makes them unsuitable for those who may wish to conceive.

GnRH analogues ± addback HRT: are of proven benefit for moderate to severe PMS, but with a licence for 6mths treatment only due to bone loss. Usually given with addback tibolone (fewer side effects and bone loss). ‘GnRH test’ useful for those considering hysterectomy and bilateral salpingo-oophrectomy (BSO) for severe symptoms.

SSRIs/selective noradrenalin reuptake inhibitors: a meta-analysis confirms benefit for continuous and luteal phase only treatment. No current licence in the UK so careful documentation is required as some women are reluctant to accept antidepressants. Side effects may be problematic, but are reduced by luteal phase only dosing.

Antidepressants: tricyclics and anxiolytics have benefits for selected patients as indicated in at least 9 studies.

Two trials have confirmed a benefit of removal of the ovarian trigger with the uterus to avoid the need for combined HRT as definitive treatment for severe PMS. However, it is generally recommended that a ‘GnRH test’ is performed to ensure that a benefit will be realized and/or another indication for hysterectomy is present.

Self-help techniques for managing PMS
Dietary alteration

Possible benefit with less fat, sugar, salt, caffeine, and alcohol, frequent

starchy meals, more fibre, fruit, and vegetables, and 4-hourly

small snacks.

Dietary supplements

Vitamin B6: possible benefit for PMS symptoms and depressive symptoms.

Vitamin E: studies small, but promising.

Calcium: two studies (1200–1600mg) revealed some improvement in symptoms.

Magnesium: appears most beneficial for premenstrual anxiety.

Evening primrose oil: of value for mastalgia only.

Exercise

Moderate regular aerobic exercise promoting cardiovascular work is beneficial (three controlled studies).

Stress reduction

Relaxation techniques, yoga, meditation, breathing techniques, and encouragement of healthier lifestyle may also help.

Cognitive behavioural therapy

Several studies have indicated a long-term benefit for women with PMS.

Complementary and alternative therapies used in PMS

Acupuncture: several RCTs show positive data for dysmenorrhoea.

Homeopathy: in a pilot study (n = 20), improvement in 90% compared to placebo.

Progesterone and wild yam: no benefit demonstrated in many studies.

Phytoestrogens: possible benefit for PMS symptoms (may be difficult to incorporate into a western diet).

Herbal remedies:

two good trials confirm benefit of Vitex agnus castus

(20mg od)

St John’s wort may also be of value due to its action as an SSRI; further studies awaited.

Mind–body: aromatherapy, reflexology, photic stimulation, and magnotherapy may show some benefit, but data are sparse.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close